Mukhopadhyay Rookmini, Lambisia Arnold W, Hoang Jennifer P, Ravenhill Benjamin J, Agoti Charles N, Krishna Benjamin A, Houldcroft Charlotte J
Department of Genetics, University of Cambridge, Cambridge, UK.
Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
J Med Virol. 2025 Feb;97(2):e70222. doi: 10.1002/jmv.70222.
Human adenoviruses (HAdVs) cause diverse disease presentations as pathogens and are also used as viral vectors for vaccines and gene therapy products. Pre-existing adaptive immune responses to HAdV are known to influence symptom severity, viral clearance and the success of viral vectored products. Of note, approximately 50% of the UK's adult population has received at least one dose of a chimpanzee adenovirus vectored SARS-CoV-2 vaccine (ChAdOx1) since January 2021. We used FluoroSpot analysis to quantify the interferon-gamma (IFNγ) and interleukin-2 (IL2) responses of healthy blood donors to HAdV species A, B, C, D and F and chimpanzee adenovirus Y25, related to HAdV species E. We find that cellular immune responses to multiple species of human adenovirus are ubiquitous among healthy adult blood donors and that stimulating PBMC with whole hexon peptide libraries induces a significantly greater IFNγ and IL2 response than using selected peptide pools alone. We then compared the cellular immune responses of ChAdOx1 recipients and control donors using PBMC collected in 2021 and found that homotypic and heterotypic IFNγ responses were significantly boosted in ChAdOx1 recipients but not controls. Finally, we show that in PBMC derived from blood donors, IFNγ responses are made to both conserved and variable regions of the hexon protein. Future vaccination campaigns using adenoviral vectored vaccines will need to account for the pre-existing exposure of recipients to both circulating HAdVs and vaccines such as ChAdOx1, which convey polyfunctional antiviral T cell responses to even low seroprevalence HAdV types.
人类腺病毒(HAdVs)作为病原体可导致多种疾病表现,同时也被用作疫苗和基因治疗产品的病毒载体。已知对HAdV预先存在的适应性免疫反应会影响症状严重程度、病毒清除以及病毒载体产品的成功率。值得注意的是,自2021年1月以来,英国约50%的成年人口已接种至少一剂黑猩猩腺病毒载体的SARS-CoV-2疫苗(ChAdOx1)。我们使用FluoroSpot分析来量化健康献血者对HAdV A、B、C、D和F型以及与HAdV E型相关的黑猩猩腺病毒Y25的干扰素-γ(IFNγ)和白细胞介素-2(IL2)反应。我们发现,健康成年献血者中对多种人类腺病毒的细胞免疫反应普遍存在,并且用完整六邻体肽文库刺激外周血单个核细胞(PBMC)所诱导的IFNγ和IL2反应明显大于仅使用选定肽库的情况。然后,我们使用在2021年收集的PBMC比较了ChAdOx1接种者和对照献血者的细胞免疫反应,发现ChAdOx1接种者的同型和异型IFNγ反应显著增强,而对照者则不然。最后,我们表明,在来自献血者的PBMC中,对六邻体蛋白的保守区和可变区均产生了IFNγ反应。未来使用腺病毒载体疫苗的疫苗接种活动将需要考虑接种者预先接触过循环中的HAdV以及诸如ChAdOx1等疫苗的情况,这些疫苗会对即使血清阳性率较低的HAdV类型产生多功能抗病毒T细胞反应。